ARLINGTON, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

) has been revised to $31.36 / share. This is an increase of 23.00% from the prior estimate of $25.50 dated September 10, 2025. The price target is an average of many targets provided by analysts. The ...

(RTTNews) - KALA Bio, Inc. (KALA) on Monday announced that its CHASE Phase 2b study of KPI-012 for the treatment of persistent corneal epithelial defect (PCED) did not meet the primary endpoint of ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kala Pharmaceuticals ( (KALA)) has shared ...

Shares of Kala Pharmaceuticals surged Wednesday after the small biotechnology company announced a drug candidate for a rare eye disease. The Food and Drug Administration has accepted Kala's ...